A Phase II Trial to Evaluate the Efficiency and Safety of Serplulimab Plus Chemotherapy as Conversion Therapy in NSCLC

Phase 2

Recruiting

• Conditions: Unresectable Lung Non-Small Cell Carcinoma
• Interventions: Procedure: serplulimab plus chemotherapy as conversion treatment

• Registration Number: NCT05837052
• Lead Sponsor: Zhejiang University

Brief Summary

This is a phase II, single-arm study to evaluate the efficacy and safety of Serplulimab plus chemotherapy as conversion treatment in patients with stage IIIB-IVA oligometastatic non-small cell lung cancer.

Detailed Description

This single-arm, open-label, prospective phase II clinical trial was designed to evaluate the efficacy and safety of Serplulimab plus chemotherapy as conversion treatment in patients with stage IIIB-IVA oligometastatic non-small cell lung cancer.

The primary endpoints were the rate of NSCLC converting to resectable tumors and the 1-year progression-free survival (PFS) rate.The secondary endpoints included the rates of R0 resection, major pathological response (MPR) and pathological complete response (pCR), overall survival (OS) and PFS. Multi-omics analysis will be performed to identify potential biomarkers for treatment response.

Study Timeline

• Study First Submitted: 2023-04-17
• Study First Submitted QC: 2023-04-27
• Study First Posted: 2023-05-01
• Study Start: 2023-05-15
• Status Verified: 2023-07
• Last Update Submitted: 2023-07-14
• Last Update Posted: 2023-07-17
• Primary Completion: 2025-06-30
• Study Completion: 2026-12-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 49

Inclusion Criteria

1. Patients should voluntarily join this study and sign the informed consent form
2. NSCLC patients diagnosed by cytology or histology and not previously receiving anti-tumor treatments (including systemic treatments, local treatments .etc)
3. Patients with IIIB - IVA oligometastatic NSCLC : (a) IIIB - IIIC stage (T1-4N2-3): patients are not suitable or refuse to receive upfront surgical resection or radiotherapy; (b) oligometastatic stage IV (T1-3N0-2): radical resection/radiotherapy is feasible for metastatic lesions (the number of metastases being up to 3, and the maximum diameter of metastases being up to 2cm)
4. After evaluation by MDT, upfront surgical resection is not the preferred treatment, but after induction systemic treatments, radical resection of the primary tumor is feasible, and radical resection/radiotherapy is feasible for extrathoracic metastases (if any)
5. Age from 18 to 75 years old, both male and female
6. ECOG score 0-1
7. According to the RECIST v1.1 , patients should have at least one measurable lesion
8. For suspicious mediastinal lymph nodes (including pathological enlargement or PET-CT indicating malignancy, etc.), further sampling is required for pathological diagnosis by EUBS, thoracoscopy, or mediastinoscopy
9. According clinical evaluation, the lung function of patients (such as FVC, FEV1, TLC, FRC, DLco, etc.) should be sufficient for pneumonectomy
10. The function of important organs should meet the following requirements: absolute count of neutrophils ≥ 1.5 × 109/L； Platelets ≥ 100 × 109/L； Hemoglobin ≥ 90g/L; Serum albumin ≥ 35g/L; Thyroid hormone (TSH) ≤ 1 × ULN； Serum bilirubin ≤ 1.5 × ULN； ALT and AST ≤ 3 × ULN； International standardized ratio (INR) ≤ 1.5 or prothrombin time (PT) ≤ 1.5 × ULN； Serum creatinine ≤ 1.5 × ULN
11. Female patients at childbearing age are required to use contraceptive measures; for male patients whose partners are women at childbearing age, effective methods of contraception should be used during the trial period

Exclusion Criteria

Patients who meet any of the following conditions will not be enrolled in this study:

1. NSCLC patients have sensitive EGFR mutation, EML4-ALK fusion or other forms of ALK gene changes
2. Patients have previously received immune checkpoint inhibitors such as PD-1/ PD-L1/CTLA4 antibody
3. Patients with other primary malignancies within the past 3 years (excluding cured skin basal cell carcinoma and cervical carcinoma in situ)
4. Patients with active hepatitis B/C
5. Patients with any active autoimmune diseases or a history of autoimmune diseases
6. Patients who are using immunosuppressive agents or require systemic hormone therapy
7. Patients with hypertension but without good control even through antihypertensive medication treatment ; patients with clinical symptoms or diseases related to unsatisfying cardiac function
8. Patients with abnormal coagulation function (INR>2.0, PT>16s)
9. Arterial/venous thrombotic events occurred before screening within 6 months
10. Patients with active infection
11. Patients with congenital or acquired immune dysfunction (such as HIV infection)
12. According to the judgment of the researchers, patients have other factors that may affect the results of the research or cause the research to be terminated

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Serplulimab plus chemotherapy	serplulimab plus chemotherapy as conversion treatment	Patients with unresectable NSCLC will receive 3-4 cycles of serplulimab plus chemotherapy as the conversion treatment (serplulimab 300mg d1 q3w; carboplatin (AUC 5) on day 1, and pemetrexed (500 mg/m2 for adenocar- cinoma) or nab-paclitaxel (260 mg/m2 for squamous carcinoma) d1 q3w), and then curative pneumonectomy will be provided for patients who are suitable for primary tumor resection. Locoregional ablative treatments will be performed for metastatic lesions. Maintenance treatment with PD-1 antibody q3w will continue up to 12 months or disease progression after surgery.

Primary Outcome Measures

Name	Time	Method
the rate of NSCLC converting to resectable tumors	up to 16 weeks	the proportion of unresectable NSCLC patients who are converted to being suitable for radical pneumonectomy after 3-4 cycles serplulimab plus chemotherapy
the 1-year progression-free survival (PFS) rate	up to one year	the proportion of patients who are progression-free after pneumonectomy

Secondary Outcome Measures

Name	Time	Method
the rate of pathological complete response (pCR)	up to 16 weeks	the proportion of patients who achieve pCR among those receiving pneumonectomy
the rate of R0 resection	immediately after the surgery	the proportion of R0 resection in patients who receive pneumonectomy
Progression-free survival (PFS)	up to five years	The duration from the date of initial treatment to the date of disease progression or death due to any cause
Overall survival (OS)	up to five years	The duration from the date of initial treatment to the date of death due to any cause
the rate of major pathological response (MPR)	up to 16 weeks	the proportion of patients who achieve MRP among those receiving pneumonectomy

Trial Locations

Locations (1)

Zhejiang University; 🇨🇳 Hangzhou, Zhejiang, China